Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3

3(50.0%)

N/A

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03646344Phase 3Terminated

Heme Arginate in Transplantation Study

Role: collaborator

NCT03994783Phase 3Terminated

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

Role: collaborator

NCT04084145Active Not Recruiting

National Unified Renal Translation Research Enterprise - Chronic Kidney Disease

Role: collaborator

NCT06767592Not ApplicableRecruiting

A Study of Probiotics in IgA Nephropathy

Role: collaborator

NCT03956576Not ApplicableCompleted

Apelin as a Potential Treatment for Chronic Kidney Disease

Role: collaborator

NCT02042768Completed

Observational Study of Glucose Metabolism and How Dialysate Glucose Affects This

Role: collaborator

NCT03288532Phase 3Recruiting

Renal Adjuvant MultiPle Arm Randomised Trial

Role: collaborator

NCT01671228Phase 1Completed

Developing and Evaluating the Yorkshire Dialysis Decision Aid

Role: collaborator

All 8 trials loaded